Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent Biosolutions (NY: EBS )

1.930 +0.050 (+2.66%)
Official Closing Price Updated: 7:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,810,837
Open 1.940
Bid (Size) 2.740 (80)
Ask (Size) 2.800 (12)
Prev. Close 1.880
Today's Range 1.870 - 1.995
52wk Range 1.420 - 10.88
Shares Outstanding 52,200,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Emergent BioSolutions (EBS) Q1 2024 Earnings Call Transcript
EBS earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
EBS Stock Earnings: Emergent BioSolutions Beats EPS, Beats Revenue for Q1 2024
EBS stock results show that Emergent BioSolutions beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-25.48%
-25.48%
1 Month
-16.09%
-16.09%
3 Month
+15.57%
+15.57%
6 Month
-1.53%
-1.53%
1 Year
-76.66%
-76.66%

More News

Read More
Emergent BioSolutions Reports First Quarter 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Emergent BioSolutions Announces Amendment to its Existing Credit Facility
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024
From Emergent BioSolutions
Via GlobeNewswire
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Emergent BioSolutions's Earnings: A Preview
Via Benzinga
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility
From Emergent BioSolutions
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Emergent BioSolutions (EBS) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
EBS Stock Earnings: Emergent BioSolutions Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Emergent BioSolutions Reports Q4 Results, Amends Credit Agreement
Via Benzinga
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Earnings Scheduled For March 6, 2024
Via Benzinga
Earnings Scheduled For March 5, 2024
Via Benzinga
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
From Emergent BioSolutions
Via GlobeNewswire
What's Going On Emergent BioSolutions Shares Today?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.